Ma et al found that GRK2, by downregulating the early growth response-1 (EGR1) expression, inhibited the IGF1-induced HCC cell growth and migration, suggesting that GRK2 might represent a therapeutic approach in HCC treatment [78]. Here, EGR1 is linked to hepatocellular carcinoma.